The total trade value of SCO Member States has increased nearly 100 times over the past 20 years

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

China’s E-bike Brands Going Global: A Review of 26 Leading Players

With the global e-bike market continuing to expand, Chinese e-bike companies are gradually shifting from being a manufacturing powerhouse to becoming a meaningful force in global competition. This article reviews a group of Chinese e-bike players and examines their overseas positioning and market entry paths—looking at how Chinese brands are securing a foothold in the next wave of globalization.

An Initial Assessment of Market Entry Opportunities in Central Asia

Over the past three years, Central Asia has been moving beyond its traditional role as a resource-dependent region and is emerging as a new growth market attracting attention from multiple industries.

Unpacking Japanese E-commerce：The Overlooked 120 Million Consumers

Japan is a demanding but high-value market. Chinese sellers are growing fast, yet success requires more than low prices—clear manuals, strong quality, 24/7 service, and trust. Consumption is polarizing, and aging buyers remain active. Long-term branding and localization are key.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.